


## Supplementary Materials and Methods


**Table S1.** Primers used for *NRG* fusions and *HER2* transmembrane domain.

<b>Gene</b>	<b>Forward</b>	<b>Reverse</b>
<i>SLC3A2-NRG1</i> fusion	5' - CTGACTTGCTGCAGATCGAC -3'	5' - ATCTCGAGGGGTTTGAAAGG -3'
<i>VAMP2-NRG1</i> fusion	5' - GCCATCATCCTCATCATCATC -3'	5' - ATCTCGAGGGGTTTGAAAGG -3'
<i>HER2</i> transmembrane domain (TMD)	5' - CGGTGTGAAACCTGACCTCT -3'	5' - CAGCTCCGTCTCTTTCAGGA -3'

**a**



**b**



**Supplementary Figure S1.** Kaplan-Meier curves of overall survival (OS) of (a) Stage I (b) Stage IV patients with pulmonary invasive mucinous adenocarcinoma and non-IMA type adenocarcinoma.